This bispecific antibody recognizing c-Met and Her3 at the same time shows an improved effect for inhibiting cancer cell compared to anti-c-Met antibody alone, by inhibiting both c-Met and Her3. The anti-c-Met/anti-Her3 bispecific antibody can also obtain efficient effects even when applied to patients who have developed resistance against pre-existing anti-Her3 antibodies. It is also capable of inhibiting the activity of c-Met and Her3 by the internalization and degradation of c-Met and Her3.

Specifications

Target

Target 1
MET

Gene ID
4233

UniProt ID
A0A024R759

Alternative Names
MET; MET proto-oncogene, receptor tyrosine kinase; HGFR; AUTS9; RCCP2; c-Met; hepatocyte growth factor receptor; SF receptor; HGF receptor; HGF/SF receptor; proto-oncogene c-Met; scatter factor receptor; tyrosine-protein kinase Met; met proto-oncogene tyrosine kinase

Target 2
ErbB-3

Gene ID
2065

UniProt ID
P21860

Alternative Names
ERBB3; erb-b2 receptor tyrosine kinase 3; HER3; LCCS2; ErbB-3; c-erbB3; erbB3-S; MDA-BF-1; c-erbB-3; p180-ErbB3; p45-sErbB3; p85-sErbB3; receptor tyrosine-protein kinase erbB-3; proto-oncogene-like protein c-ErbB-3; human epidermal growth factor receptor 3; tyrosine kinase-type cell surface receptor HER3; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3

Downloads

Customer Reviews and Q&As